| Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial.Diabetes Metab J | PMID 38763510PMC11307122 | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Specialist physiotherapy for functional motor disorder in England and Scotland (Physio4FMD): a pragmatic, multicentre, phase 3 randomised controlled trial.Lancet Neurol | PMID 38768621无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II).Eur J Drug Metab Pharmacokinet | PMID 38769284无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data.Adv Ther | PMID 38775925PMC11213751 | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.Lancet Neurol | PMID 38782015无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial.Lancet HIV | PMID 38788744PMC11700562 | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.Int J Hematol | PMID 38796666PMC11226530 | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial.Asian J Psychiatr | PMID 38797087无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study.Adv Ther | PMID 38802635PMC11213736 | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial.Oral Oncol | PMID 38820889无 PMCID | 2024-Jul | 0.85 | The record is from a definitive randomized controlled oncology trial, but it reports on a secondary analysis of a toxicity outcome (risk prediction model for cisplatin-induced AKI) rather than a primary or secondary efficacy endpoint like overall survival, progression-free survival, or recurrence. | 待处理 |
| Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.Lung Cancer | PMID 38820979无 PMCID | 2024-Jul | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis.Adv Ther | PMID 38833140无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial.Ann Hematol | PMID 38842566PMC11224074 | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study.Lancet Oncol | PMID 38848742无 PMCID | 2024-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Acute Intermittent Hypoxia With High-Intensity Gait Training in Chronic Stroke: A Phase II Randomized Crossover Trial.Stroke | PMID 38860389PMC11196200 | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of mixture of ivy leaf extract and coptidis rhizome in the treatment of acute bronchitis: multicenter, randomized, double-blinded, active-controlled, parallel, therapeutic confirmatory clinical trial.Curr Med Res Opin | PMID 38889376无 PMCID | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.Lancet Oncol | PMID 38936378PMC11550893 | 2024-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study.Clin Drug Investig | PMID 38937403PMC11263219 | 2024-Jul | 0.95 | Study is an original, randomized, Phase III oncology trial of a drug (biosimilar) intervention with a primary efficacy endpoint of objective response rate (categorical), not a time-to-event endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR reporting. | 待处理 |
| Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial.Eur J Paediatr Neurol | PMID 38959712PMC11283350 | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Morbidity and Mortality After Laparoscopy-Assisted Distal Gastrectomy and Totally Laparoscopic Distal Gastrectomy to Treat Gastric Cancer: An Interim Report: A Phase III Multicenter, Prospective, Randomized Trial (The KLASS-07 Trial).J Gastric Cancer | PMID 38960885PMC11224718 | 2024-Jul | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa.J Int AIDS Soc | PMID 38978403PMC11231445 | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNA-Related Dilated Cardiomyopathy.Circ Heart Fail | PMID 38979608PMC11244753 | 2024-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.Lancet | PMID 38851203无 PMCID | 2024-Jun-29 | 1.00 | All required criteria are explicitly met: oncology, human, randomized, Phase III, time-to-event endpoint, drug intervention, and original result report. | 待处理 |
| Re-examining the factor structure of the Insomnia Severity Index (ISI) and defining the meaningful within-individual change (MWIC) for subjects with insomnia disorder in two phase III clinical trials of the efficacy of lemborexant.J Patient Rep Outcomes | PMID 38951287PMC11217251 | 2024-Jun-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis.Nephrol Dial Transplant | PMID 37968132PMC11210984 | 2024-Jun-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial.Crit Care | PMID 38943192PMC11214248 | 2024-Jun-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.N Engl J Med | PMID 38767614无 PMCID | 2024-Jun-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Reteplase versus Alteplase for Acute Ischemic Stroke.N Engl J Med | PMID 38884332无 PMCID | 2024-Jun-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age.N Engl J Med | PMID 38924731无 PMCID | 2024-Jun-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis.N Engl J Med | PMID 38924732无 PMCID | 2024-Jun-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.Blood Adv | PMID 38607410PMC11225676 | 2024-Jun-25 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Post hoc subgroup analysis of Asian children with paediatric GHD from the global phase 3 efficacy and safety study of once-weekly somatrogon vs. once-daily somatropin.J Pediatr Endocrinol Metab | PMID 38717038无 PMCID | 2024-Jun-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.Arthritis Res Ther | PMID 38918871PMC11197242 | 2024-Jun-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.Lancet | PMID 38824941无 PMCID | 2024-Jun-22 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet | PMID 38843860PMC11740396 | 2024-Jun-22 | 0.95 | The trial meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result. However, it is excluded because the primary efficacy endpoint is objective response rate (ORR), which is not a time-to-event endpoint. The abstract does not report a time-to-event outcome like OS, PFS, DFS, EFS, RFS, or TTP, nor does it mention Kaplan-Meier estimates or hazard ratios for such an endpoint. | 待处理 |
| Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS).Br J Dermatol | PMID 38133615无 PMCID | 2024-Jun-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of bilastine vs. levocetirizine for the treatment of chronic idiopathic urticaria: A multicenter, double-blind, double-dummy, phase III, non-inferiority, randomized clinical trial.Chin Med J (Engl) | PMID 38557589PMC11188862 | 2024-Jun-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease.J Clin Oncol | PMID 38603646无 PMCID | 2024-Jun-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial.Vaccine | PMID 38734495无 PMCID | 2024-Jun-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bilastine 0.6% Preservative-free Eye Drops: A Once-daily Treatment for Allergic Conjunctivitis.J Investig Allergol Clin Immunol | PMID 36811846无 PMCID | 2024-Jun-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).J Clin Endocrinol Metab | PMID 38252888PMC11180500 | 2024-Jun-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial.J Clin Psychiatry | PMID 38917366无 PMCID | 2024-Jun-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.Lancet | PMID 38768626无 PMCID | 2024-Jun-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.Clin Infect Dis | PMID 38253338PMC11175669 | 2024-Jun-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT).Clin Infect Dis | PMID 38297916无 PMCID | 2024-Jun-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.Clin Infect Dis | PMID 38305378PMC11175683 | 2024-Jun-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.Clin Infect Dis | PMID 38462673PMC11175687 | 2024-Jun-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and Safety of a Purified Vero Rabies Vaccine-Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial.Clin Infect Dis | PMID 38478634PMC11175674 | 2024-Jun-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.Blood | PMID 38557775PMC11208295 | 2024-Jun-13 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A single-center, assessor-blinded, randomized controlled clinical trial to test the safety and efficacy of a novel brain-computer interface controlled functional electrical stimulation (BCI-FES) intervention for gait rehabilitation in the chronic stroke population.BMC Neurol | PMID 38872109PMC11170800 | 2024-Jun-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |